Literature DB >> 35386094

Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.

Antonio Gallo1,2, Reed Mszar3,4, Marcio Hiroshi Miname5,6.   

Abstract

PURPOSE OF REVIEW: The high variability of cardiovascular risk in heterozygous familial hypercholesterolemia (HeFH) is a challenge for therapeutical management. Subclinical cardiovascular imaging represents a tool to overcome this challenge. The purpose of this review is to update the reader on the most recent findings on the non-invasive detection of atherosclerotic burden by carotid doppler ultrasound (US), coronary artery calcium (CAC) score, and computed tomography coronary angiography (CTCA) for the optimization of risk stratification in HeFH subjects. RECENT
FINDINGS: Carotid ultrasound (US) proved its efficacy in the long-term follow-up of HeFH children treated early on with statins, showing a significant reduction of atherosclerotic progression compared to untreated unaffected siblings. The added value of CAC score has been confirmed to predict the risk of cardiovascular events and improve risk stratification provided by available risk equations in asymptomatic HeFH subjects from large prospective cross-national cohorts. Additionally, CTCA provides detailed information on plaque quality and stability, but its role in primary prevention HeFH subjects needs to be further explored. Cardiovascular imaging for the detection of subclinical atherosclerotic cardiovascular disease in HeFH is a promising tool to improve diagnostic and therapeutical management of this undertreated and late-diagnosed disease.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular disease; Cardiovascular imaging; Familial hypercholesterolemia; Risk stratification

Mesh:

Substances:

Year:  2022        PMID: 35386094     DOI: 10.1007/s11883-022-01017-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  48 in total

1.  Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.

Authors:  Joost Besseling; G Kees Hovingh; Roeland Huijgen; John J P Kastelein; Barbara A Hutten
Journal:  J Am Coll Cardiol       Date:  2016-07-19       Impact factor: 24.094

2.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system.

Authors:  Noura S Abul-Husn; Kandamurugu Manickam; Laney K Jones; Eric A Wright; Dustin N Hartzel; Claudia Gonzaga-Jauregui; Colm O'Dushlaine; Joseph B Leader; H Lester Kirchner; D'Andra M Lindbuchler; Marci L Barr; Monica A Giovanni; Marylyn D Ritchie; John D Overton; Jeffrey G Reid; Raghu P R Metpally; Amr H Wardeh; Ingrid B Borecki; George D Yancopoulos; Aris Baras; Alan R Shuldiner; Omri Gottesman; David H Ledbetter; David J Carey; Frederick E Dewey; Michael F Murray
Journal:  Science       Date:  2016-12-23       Impact factor: 47.728

3.  Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.

Authors:  Pengwei Hu; Kanika I Dharmayat; Kausik K Ray; Antonio J Vallejo-Vaz; Christophe A T Stevens; Mansour T A Sharabiani; Rebecca S Jones; Gerald F Watts; Jacques Genest
Journal:  Circulation       Date:  2020-05-29       Impact factor: 29.690

4.  Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.

Authors:  Sabina O Beheshti; Christian M Madsen; Anette Varbo; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2020-05-26       Impact factor: 24.094

5.  Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.

Authors:  Joost Besseling; Iris Kindt; Michel Hof; John J P Kastelein; Barbara A Hutten; G Kees Hovingh
Journal:  Atherosclerosis       Date:  2014-01-11       Impact factor: 5.162

6.  Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).

Authors:  Leopoldo Pérez de Isla; Rodrigo Alonso; Nelva Mata; Adriana Saltijeral; Ovidio Muñiz; Patricia Rubio-Marin; José L Diaz-Diaz; Francisco Fuentes; Raimundo de Andrés; Daniel Zambón; Jesús Galiana; Mar Piedecausa; Rocio Aguado; Daniel Mosquera; José I Vidal; Enrique Ruiz; Laura Manjón; Marta Mauri; Teresa Padró; José P Miramontes; Pedro Mata
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-21       Impact factor: 8.311

7.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

Authors:  A H Pijlman; R Huijgen; S N Verhagen; B P M Imholz; A H Liem; J J P Kastelein; E J Abbink; A F H Stalenhoef; F L J Visseren
Journal:  Atherosclerosis       Date:  2009-09-15       Impact factor: 5.162

8.  Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors.

Authors:  R Alonso; N Mata; S Castillo; F Fuentes; P Saenz; O Muñiz; J Galiana; R Figueras; J L Diaz; P Gomez-Enterría; M Mauri; M Piedecausa; L Irigoyen; R Aguado; P Mata
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

9.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

10.  Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Authors:  S E Humphries; J A Cooper; M Seed; N Capps; P N Durrington; B Jones; I F W McDowell; H Soran; H A W Neil
Journal:  Atherosclerosis       Date:  2018-05-01       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.